GB Sciences Inc (GBLX)

[3DYOGI]

GB Sciences Inc. (OTCQB: GBLX) recently completed a pivot away from developing agricultural technologies and toward medical marijuana cultivation and cannabinoid biopharmaceutical development. By doing so, the company aims to generate near-term revenue to help offset the cost of developing cannabinoid-based biopharmaceuticals with blockbuster potential. Investors may want to take a closer look at the stock given the new focus.

GB Sciences matching cannabis strains with disease targets
GBX01
Cancer Treatments
Reduces Nauseu
Increases Appetite

GBX02
Cardio- protection
Fights ischemia
Increases circulation

GBX03
Metabolic Syndrome
Lowers blood sugar
Suppresses appetite

GBX04
Pain Management
Reduces aches & pains
Reduces Chronic pain


GBX05
Neurological Disorder
induces sleep
relives anxiety
Protects Nerves
Lessens spasms Fights psychosis
Combats depression
Reduces epileptic seizures

GBX06
Inflammation
Relieves psoriasis
Decrease gastric inflammation

GBX07
Compromised Immune System
Immunostimulant
fights nausea
reduces wasting syndrome
--------------------------------------------------------------------------------------------------------
I expect significant growth and share price surge in the near future. 6.6 Million float right timing great investment.